<DOC>
	<DOC>NCT02748408</DOC>
	<brief_summary>This is a Post-Marketing Surveillance of SMS femoral stem prosthesis.</brief_summary>
	<brief_title>The Medacta International SMS Post-Marketing Surveillance Study</brief_title>
	<detailed_description />
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Hip Dislocation</mesh_term>
	<mesh_term>Hip Dislocation, Congenital</mesh_term>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Femur Head Necrosis</mesh_term>
	<criteria>Individuals with a severely painful and/or disabling hip joint with osteoarthritis, traumatic arthritis or developmental dysplasia of the hip or avascular necrosis of the femoral head. In order to take part in this study, all study participants must be between the ages of 18 and 75 years of age, at the time of surgery. Scheduled for a primary total hip replacement. Active infection Pregnancy Mental illness where the known condition is likely to compromise the patient's ability to consent, affect the patient's assessment of their progress or complete the 10 year cycle of followup appointments and reviews Grossly distorted anatomy (surgeon's discretion) Osteomalacia where uncemented implant fixation is contraindicated Active rheumatoid arthritis. Osteoporosis Metabolic disorders which may impair bone formation where uncemented implant fixation is contraindicated Muscular atrophy or neuromuscular disease Allergy to implant material Any patient who cannot or will not provide informed consent for participation in the study Those whose prospects for a recovery to independent mobility would be compromised by known coexistent, medical problems</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>